Immunohistopathologic Findings of Cesarean Scar Niche

NCT ID: NCT06466343

Last Updated: 2024-06-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-01

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Niche is iatrogenic pouch like defect, present on the uterine isthmus' anterior wall where a previous caesarean section scar was made. Still, a niche has generally been defined as the myometrium's depression of at least 2 mm (Lumbanraja et al., 2024).

The literature is lacking in information about the accurate histopathologic characteristics of cesarean scar niche ridges that have been removed by hysteroscopy, as well as what critical findings to highlight and what gynaecologists can anticipate from pathology reports of cesarean scar niche specimens (AbdullGaffar \& Almulla ,2022).

In this study the aim of the work is to study the histopathologic findings in cesarean scar niche specimens repaired by hysteroscopy in our institution, identify the causes of local thinning of the uterine scar after c-section to direct gynecologists regarding the efficacy of their hysteroscopic corrective repair of cesarean scar niche concerning the amelioration of symptoms, restoration of fertility, and patient follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects \& Methods Study will be conducted on non-pregnant women with symptomatic uterine scar niche after lower segment CS at Obstetrics and Gynecology department at Sohag University Hospitals.

Patient recruitment:

All eligible patients attending at the Obstetrics and Gynecology outpatient clinic at the department will be approached by the attending physician A through explanation about the nature of the study to each patient. All patients agreeing to participate in the study will be asked to sign the informed written consent before enrollment in the study.

Ultrasound examination:

Uterine scar niche will be diagnosed by transvaginal Logic P7, GE US (frequency 50/60Hz) postmenstrual. In longitudinal plane of the uterus at anterior wall at site of CS, the depth, width, and residual myometrial thickness will be measured. All measures will be done by single operator.

Niche is iatrogenic pouch like defect, present on the uterine isthmus' anterior wall where a previous caesarean section scar was made.The myometrium's depression of at least 2 mm.

Operative procedure:

For every patient, related clinical data will be gathered, age, parity, clinical presentation, number of previous CSs, history of secondary infertility, history of previous niche repair surgeries, and follow-up data will be included in this.

Operative hysteroscopy will be used for surgical treatment in the cases.

Histopathological examination:

The hematoxylin and eosin (H\&E) slides will be inspected to identify any changes related to the mucosa as well as the types of lining mucosa of the resected edges, the types of stroma and stroma-associated changes, the presence of myometrial tissue, and scarring. Slides will be also screened for inflammatory, hemorrhagic, degenerative changes, foreign body giant cell reaction and Masson trichrome stain: for staining of fibrosis (Higuchi et al., 2022).

Immunohistochemistry:

Using a sliding microtome, all paraffin-embedded blocks will be cut into 4-µm-thick sections. The parts will be floated in a water bath at 42°C before being put on slides. The antigens will be recovered in an antigen retrieval reagent following deparaffinization, CD3: a marker for T lymphocyte, CD20: a marker for B lymphocytes and CD34: a marker for angiogenesis.

Follow up:

Patients will be asked to come after 3 months for asking about improvement of symptoms, quality of life, transvaginal US evaluation will be done, and a questionnaire will be filled out (Herdman et al.,2003)

Statistical analysis:

The collected data was organized, tabulated, and statistically analyzed using Statistical Package for Social Science (SPSS) version 16 (SPSS Inc, USA). For quantitative data, mean and standard deviation (SD) will be calculated and for comparison between two means, the students (t) test will be used. For qualitative data, the frequency and percent distribution will be calculated and for comparison between groups, chi square (X2) will be used. For interpretation of results p value will be significant if less than 0.05.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cesarean Scar Niche

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Study will be conducted on non-pregnant women with symptomatic uterine scar niche after lower segment CS at Obstetrics and Gynecology department at Sohag University Hospitals.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

symptomatic non pregnant women

Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.

Group Type OTHER

hysteroscopic resection of lower edge of cesarean scar niche

Intervention Type PROCEDURE

Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.

The resected parts will be submitted together as one sampled specimen in one container of formaldehyde 30% (dissolved 800 ml water and 200 ml formaldehyde)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hysteroscopic resection of lower edge of cesarean scar niche

Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.

The resected parts will be submitted together as one sampled specimen in one container of formaldehyde 30% (dissolved 800 ml water and 200 ml formaldehyde)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any Women with history of previous CS once or more with period more than one year from the last CS and had CS scar defect diagnosed by TVUS.

Exclusion Criteria

* All women diagnosed with pelvic inflammatory disease, suspected with gynecological malignancy, postmenopausal women, women with heart disease, liver disease, renal impairment or bleeding tendency will be excluded from the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Abdelnasser Galal

Assistant lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

mohamed Ab Galal, A.lecturer

Role: PRINCIPAL_INVESTIGATOR

sohag faculty of medicine sohag university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag University Hospitals

Sohag, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

mohamed Ab Galal, A.Lecturer

Role: CONTACT

01095926603

Amr O Abelkareem, A.lecturer

Role: CONTACT

01001259562

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

mohamed Ab Galal, lecturer

Role: primary

01095926603

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-24-05-06MD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Laparoscopic Repair of Cesarean Scar Niche
NCT04307524 UNKNOWN PHASE2/PHASE3
Niche In CEsarean Scar Trial (NICEST)
NCT05312775 RECRUITING NA
CS Scar Impact on ART Outcomes
NCT06021886 RECRUITING